Gain Therapeutics Announces Board and Compensation Changes
Ticker: GANX · Form: 8-K · Filed: Oct 9, 2025 · CIK: 1819411
| Field | Detail |
|---|---|
| Company | Gain Therapeutics, Inc. (GANX) |
| Form Type | 8-K |
| Filed Date | Oct 9, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
Related Tickers: GNTX
TL;DR
Gain Therapeutics swapped a board member and updated exec pay. Watch for strategic shifts.
AI Summary
Gain Therapeutics, Inc. announced on October 6, 2025, a change in its board of directors and executive compensation arrangements. Specifically, the company reported the departure of a director and the election of a new director, alongside updates to the compensatory arrangements for certain officers.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board and executive compensation can introduce uncertainty regarding future strategy and leadership stability.
Key Players & Entities
- Gain Therapeutics, Inc. (company) — Registrant
- October 6, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-40237 (identifier) — SEC File Number
- 85-1726310 (identifier) — IRS Employer Identification No.
- 4800 Montgomery Lane, Suite 220 Bethesda, Maryland 20814 (address) — Principal executive offices
- (301) 500-1556 (phone_number) — Registrant's telephone number
FAQ
Who departed from the board of directors at Gain Therapeutics?
The filing indicates the departure of a director, but the specific name is not provided in this excerpt.
Who was elected to the board of directors?
The filing states the election of a new director, but the specific name is not provided in this excerpt.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is October 6, 2025.
What is the principal executive office address for Gain Therapeutics, Inc.?
The principal executive office is located at 4800 Montgomery Lane, Suite 220, Bethesda, Maryland 20814.
What specific compensatory arrangements were updated?
The filing mentions updates to the compensatory arrangements of certain officers, but the details of these arrangements are not specified in this excerpt.
Filing Stats: 433 words · 2 min read · ~1 pages · Grade level 12.1 · Accepted 2025-10-09 16:30:58
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value GANX The NASDAQ Stock Marke
Filing Documents
- tm2528203d1_8k.htm (8-K) — 23KB
- 0001104659-25-098376.txt ( ) — 186KB
- ganx-20251006.xsd (EX-101.SCH) — 3KB
- ganx-20251006_lab.xml (EX-101.LAB) — 33KB
- ganx-20251006_pre.xml (EX-101.PRE) — 22KB
- tm2528203d1_8k_htm.xml (XML) — 4KB
02 Departure of Directors or Certain
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 6, 2025, Eric Richman notified Gain Therapeutics, Inc. (the "Company") that he was resigning from the Company's Board of Directors (the "Board"), effective immediately. Mr. Richman's resignation was not as a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. On October 7, 2025, in connection with Mr. Richman's resignation, the size of the Board was reduced from eight to seven. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GAIN THERAPEUTICS, INC. Date: October 9, 2025 By: /s/ Gene Mack Name: Gene Mack Title: Chief Executive Officer